PMEF
VKTX icon

Point72 Middle East FZE’s Viking Therapeutics VKTX Stock Holding History

Point72 Middle East FZE’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-280
Closed -$4.67K – 2088
2023
Q1 		$4.67K Buy
+280
New +$2.89K ﹤0.01% 1526

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Point72 Middle East FZE's VKTX Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 280 shares — an estimated $4.67K sold.

Point72 Middle East FZE first reported a position in VKTX in Q1 2023 and held it in 1 quarter. The position peaked at $4.67K in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 280 Viking Therapeutics shares in Q2 2023, an estimated $4.67K.
  • Point72 Middle East FZE first reported a position in Viking Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Viking Therapeutics position peaked at $4.67K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.